Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST001, Pembrolizumab and Chemotherapy in Claudin18.2 Positive Gastric/GEJ Adenocarcinoma
NCT06093425Phase 3Not yet recruiting
- Sponsor
- Transcenta
- Start
- Jun 2027
- Primary completion
- Oct 2029
01
Overview
A Phase 3 trial of osemitamab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Transcenta. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
osemitamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06093425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093425.